JP5352416B2 - A blood glucose level lowering agent comprising vanadium-containing aluminum compound as an active ingredient - Google Patents
A blood glucose level lowering agent comprising vanadium-containing aluminum compound as an active ingredient Download PDFInfo
- Publication number
- JP5352416B2 JP5352416B2 JP2009245178A JP2009245178A JP5352416B2 JP 5352416 B2 JP5352416 B2 JP 5352416B2 JP 2009245178 A JP2009245178 A JP 2009245178A JP 2009245178 A JP2009245178 A JP 2009245178A JP 5352416 B2 JP5352416 B2 JP 5352416B2
- Authority
- JP
- Japan
- Prior art keywords
- vanadium
- aluminum compound
- aluminum
- blood glucose
- glucose level
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Abstract
Description
本発明は膵臓機能強化用無機化合物粒子に関するものであり、より詳しくは、アルミニウム化合物に微量のバナジウム化合物を添加して、バナジウムを固溶体として含有しているか、またはバナジウムと共沈物を形成している無機物粒子とすることにより、膵臓機能強化および活性化、すなわち、血糖値を下げ、糖尿病、膵炎糖の膵臓病の予防ないし治療に優れた効果を有する糖尿病、膵炎等の膵臓病の予防乃至治療用無機化合物粒子に関する。 The present invention relates to inorganic compound particles for enhancing pancreatic function, and more specifically, by adding a trace amount of vanadium compound to an aluminum compound and containing vanadium as a solid solution or forming a coprecipitate with vanadium. Pancreatic function strengthening and activation, that is, lowering blood sugar level, and having an excellent effect in preventing or treating diabetes, pancreatitis sugar pancreatic disease, and preventing or treating pancreatic diseases such as diabetes and pancreatitis The present invention relates to inorganic compound particles.
膵臓は、消化酵素を含む膵液を分泌し、それを消化管へ送り込む。膵液中にはたんぱく質分解酵素であるキモトリプシンやトリプシン、炭水化物の分解に働くアミラーゼ、脂質の分解に働くリパーゼなどが含まれており、食物の分解に寄与する。また膵臓の中のランゲルハウス島はインシュリン、グルカゴンなどのホルモンを血液中に分泌する。
膵臓が原因の病気としては、膵炎、糖尿病があるが、糖尿病は患者が年々増えているにもかかわらず、完治が難しい病気であるとされている。糖尿病は膵臓からのインシュリンの分泌低下や、分泌作用が十分でなくなるために起こり、重症になると網膜症や壊疽、心筋梗塞などの合併症を引きおこす。糖尿病の治療としては、インシュリンの投与がなされているが、予防・治療薬のほとんどは有機物ベースの治療薬（特許文献1）（特許文献2）である。近年、糖尿病にバナジウムが有効と言われ、酸化硫酸バナジウム（ＩＶ）は無機塩である為、生体膜の透過が難しく、生体内に取り込まれにくいとして、Ｖ-有機錯体も提案されている（特許文献3）。
The pancreas secretes pancreatic juice containing digestive enzymes and sends it to the digestive tract. The pancreatic juice contains protein-degrading enzymes chymotrypsin and trypsin, amylase that works to break down carbohydrates, lipase that works to break down lipids, etc., and contributes to the breakdown of food. Langerhaus Island in the pancreas secretes hormones such as insulin and glucagon into the blood.
As diseases caused by the pancreas, there are pancreatitis and diabetes, but it is said that diabetes is a disease that is difficult to cure even though the number of patients is increasing year by year. Diabetes mellitus occurs because insulin secretion from the pancreas is decreased or the secretory action is insufficient, and when it becomes severe, it causes complications such as retinopathy, gangrene, and myocardial infarction. Insulin is administered as a treatment for diabetes, but most of the preventive / therapeutic drugs are organic-based therapeutic drugs (Patent Document 1) (Patent Document 2). In recent years, vanadium is said to be effective for diabetes, and since vanadium oxide (IV) sulfate is an inorganic salt, V-organic complexes have been proposed as being difficult to permeate through biological membranes and difficult to be taken into living bodies (patents). Reference 3).
本発明の目的は、糖尿病、膵炎等の膵臓病の治療乃至予防、さらに膵臓機能強化乃至活性化剤、として有用な無機化合物を提供することである。すなわち、微量のバナジウムをアルミニウム化合物に固溶または共沈させた無機化合物粒子を提供することである。 An object of the present invention is to provide an inorganic compound useful as a treatment or prevention of pancreatic diseases such as diabetes and pancreatitis, and further as a pancreatic function enhancing or activating agent. That is, it is to provide inorganic compound particles in which a trace amount of vanadium is dissolved or coprecipitated in an aluminum compound.
本発明者等は、無機系制酸剤の粘膜保護効果および潰瘍治療効果につき鋭意研究の結果、人体に不足しがちな微量のバナジウムを固溶させたアルミニウム化合物粒子が、血糖値を下げ、さらに膵臓機能の強化乃至活性化、すなわち、膵臓病の予防乃至治療に優れた効果があることをも見出した。 As a result of earnest research on the mucosal protective effect and ulcer treatment effect of inorganic antacids, the present inventors have found that aluminum compound particles in which a small amount of vanadium, which tends to be deficient in the human body, is dissolved, lowers blood glucose level , It has also been found that there is an excellent effect in enhancing or activating pancreatic function, that is, prevention or treatment of pancreatic disease.
すなわち、本発明は、以下の（１）ないし（４）の血糖値下降剤を要旨とする。
（１）原料となる水溶性アルミニウム塩に水可溶性バナジウム塩を加えて、アルミニウム塩とバナジウム塩の混合水溶液をあらかじめ調整し、バナジウムイオンの微量を、アルミニウム化合物に固溶、または共沈させた下記式（１）、
Ｍ1-x (Ｖ)x (1)
（式中、Ｍ は、乾燥水酸化アルミニウムゲル、ジヒドロキシアルミニウムアミノアセテート、水酸化アルミニウム・炭酸水素ナトリウム共沈物、合成ケイ酸アルミニウム、水酸化アルミナマグネシウムなる群より選ばれた少なくとも1種のアルミニウム化合物であり、ｘの範囲が、０．００１＜ｘ＜０．０５、すなわち、含バナジウムアルミニウム化合物におけるバナジウムの量は、金属バナジウム換算で０．００１重量％から０．０５重量％以下の範囲である。）で表される含バナジウムアルミニウム化合物を有効成分とする血糖値降下剤。
（２）上記の含バナジウムアルミニウム化合物を液体分散媒に分散させて得られる液剤である上記（１）に記載の血糖値降下剤。
（３）上記の含バナジウムアルミニウム化合物を造粒して得られる顆粒剤である上記（１）に記載の血糖値降下剤。
（４）上記の含バナジウムアルミニウム化合物を８５〜９７重量％の割合で含有する錠剤である上記（１）に記載の血糖値降下剤。
That is, the gist of the present invention is the blood glucose level lowering agent of the following (1) to (4).
(1) A water-soluble vanadium salt is added to a water-soluble aluminum salt as a raw material, a mixed aqueous solution of an aluminum salt and a vanadium salt is prepared in advance, and a minute amount of vanadium ions is dissolved or coprecipitated in an aluminum compound. Formula (1),
M 1-x (V) x (1)
(Wherein M is at least one aluminum compound selected from the group consisting of dry aluminum hydroxide gel, dihydroxyaluminum aminoacetate, aluminum hydroxide / sodium hydrogencarbonate coprecipitate, synthetic aluminum silicate, and magnesium aluminate hydroxide ) And the range of x is 0.001 <x <0.05, that is, the amount of vanadium in the vanadium-containing aluminum compound is in the range of 0.001 wt% to 0.05 wt% or less in terms of metal vanadium. .) A hypoglycemic agent comprising a vanadium-containing aluminum compound represented by
( 2 ) The blood glucose level lowering agent according to ( 1 ) above, which is a liquid agent obtained by dispersing the vanadium-containing aluminum compound in a liquid dispersion medium.
( 3 ) The blood glucose level lowering agent according to ( 1 ) above, which is a granule obtained by granulating the vanadium-containing aluminum compound .
( 4 ) The blood glucose level lowering agent according to (1), which is a tablet containing the vanadium-containing aluminum compound at a ratio of 85 to 97% by weight.
本発明者は、人間が必要とするミネラルの一つであるバナジウムイオンの微量を、アルミニウム化合物に固溶、または共沈させた上記式（１）で表されるアルミニウム化合物粒子を経口投与することにより、血糖値を下げることができることを見出した。
本発明により、糖尿病、膵炎等の膵臓病の治療乃至予防、さらに膵臓機能強化乃至活性化剤、として有用な無機化合物を提供すること、すなわち、微量のバナジウムをアルミニウム化合物に固溶または共沈させた無機化合物粒子を提供することができる。
The present inventor orally administers aluminum compound particles represented by the above formula (1) in which a minute amount of vanadium ion, which is one of minerals required by humans, is dissolved or coprecipitated in an aluminum compound. Thus, it was found that the blood glucose level can be lowered .
INDUSTRIAL APPLICABILITY According to the present invention, an inorganic compound useful as a treatment or prevention of pancreatic diseases such as diabetes and pancreatitis, and further enhancement or activation of pancreatic function is provided, that is, a trace amount of vanadium is dissolved or coprecipitated in an aluminum compound. Inorganic compound particles can be provided.
本発明の式（１）で表されるアルミニウム化合物粒子は、微量のバナジウムが固溶または共沈したものである。 The aluminum compound particles represented by the formula (1) of the present invention are those in which a small amount of vanadium is dissolved or coprecipitated.
本発明のアルミニウム化合物の製造方法は、原料となる水溶性アルミニウム塩に水可溶性バナジウム塩を加えて、アルミニウム塩とバナジウム塩の混合水溶液をあらかじめ調整しておく。バナジウム塩としては、塩化バナジウム、オキシニ塩化バナジウム、オキシ三塩化バナジウム、ニバナジン酸カリウム、メタバナジン酸カリウム、バナジン酸ナトリウム等がある。
本発明の含バナジウムアルミニウム化合物におけるバナジウムの量は、金属バナジウム換算で0.1重量％以下、好ましくは、0.05重量％以下である。上限が0.1重量％を超えると人体に悪影響を及ぼす可能性が出てくる。
In the method for producing an aluminum compound of the present invention, a water-soluble vanadium salt is added to a water-soluble aluminum salt as a raw material, and a mixed aqueous solution of an aluminum salt and a vanadium salt is prepared in advance. Examples of the vanadium salt include vanadium chloride, vanadium oxydichloride, vanadium oxytrichloride, potassium nivanadate, potassium metavanadate, and sodium vanadate.
The amount of vanadium in the vanadium-containing aluminum compound of the present invention is 0.1% by weight or less, preferably 0.05% by weight or less in terms of metal vanadium. If the upper limit exceeds 0.1% by weight, the human body may be adversely affected.
バナジウムはアルミニウム化合物に固溶しているか、もしくはアルミニウム化合物と共沈物を形成する形態で均一に含有されていることが重要である。すなわち、塩化バナジウム等のバナジウム化合物と水酸化アルミニウムを通常の方法で混合した混合物では本発明のような効果は得られない。ただし、アルミニウム化合物粒子においてバナジウムが表面に偏在固溶していても本発明の効果が減じられることはない。 It is important that vanadium is dissolved in the aluminum compound or contained uniformly in a form that forms a coprecipitate with the aluminum compound. That is, the effect of the present invention cannot be obtained with a mixture obtained by mixing a vanadium compound such as vanadium chloride and aluminum hydroxide by a usual method. However, the effect of the present invention is not diminished even if vanadium is unevenly distributed on the surface of the aluminum compound particles.
本発明のアルミニウム化合物粒子を、血糖値降下剤として、または膵臓の機能強化乃至活性化剤として、膵臓病の予防ないし治療薬として使用する場合は、粉末状、顆粒状、錠剤、カプセル剤または、スラリー状のいずれの形態でもよく、ビタミンや他のミネラル、アミノ酸、ピコリン酸、酢酸、クエン酸、グリセリン酸、モノメチオニン、賦形剤、結合剤、崩壊剤および滑沢剤等を必要に応じ添加することが出来る。 When the aluminum compound particles of the present invention are used as a hypoglycemic agent, as a pancreatic function enhancing or activating agent, and as a prophylactic or therapeutic agent for pancreatic disease, powder, granule, tablet, capsule or Any form of slurry may be used, vitamins and other minerals, amino acids, picolinic acid, acetic acid, citric acid, glyceric acid, monomethionine, excipients, binders, disintegrants and lubricants added as necessary I can do it.
賦形剤としては、乳糖、デンプン、結晶セルロース、マンニトール及び炭酸カルシウム等、結合剤としては、デンプン糊液、ゼラチン、アラビアゴム、ヒドロキシプロピルセルロース及びブドウ糖等、崩壊剤としてはゼラチン、寒天、カルボキシメチルセルロースナトリウム及び結晶セルロース等、さらに滑沢剤としてはステアリン酸マグネシウム、タルクおよびマクロゴール等通常使用される添加剤を使用して差し支えない。 Excipients include lactose, starch, crystalline cellulose, mannitol and calcium carbonate, binders include starch paste, gelatin, gum arabic, hydroxypropylcellulose and glucose, etc. disintegrants include gelatin, agar, carboxymethylcellulose Sodium, crystalline cellulose and the like, and as the lubricant, commonly used additives such as magnesium stearate, talc and macrogol may be used.
液剤を調整する場合は、本発明の含バナジウムアルミニウム化合物以外に安息香酸ナトリウム等の保存料、ｐＨ調整剤およびリンゴ酸等の甘味料および香料等を精製水に分散させる通常の調整方法を用いる。 When adjusting a liquid agent, the normal adjustment method which disperse | distributes preservatives, such as sodium benzoate, a pH adjuster, sweeteners, such as malic acid, and a fragrance | flavor other than the vanadium-containing aluminum compound of this invention in purified water, is used.
本発明のアルミニウム化合物を顆粒剤または錠剤とする場合の造粒条件や打錠条件等は、バナジウムを含まない各アルミニウム化合物の周知の条件をほぼそのまま適用してよい。例えば、含バナジウム乾燥水酸化アルミニウムゲルの打錠条件は、バナジウムを含まない乾燥水酸化アルミニウムゲルの公知の打錠条件をもとに、過度の試行錯誤なしに見出すことが出来る。 As the granulation conditions and tableting conditions when the aluminum compound of the present invention is used as granules or tablets, the well-known conditions of each aluminum compound not containing vanadium may be applied almost as they are. For example, tableting conditions for vanadium-containing dry aluminum hydroxide gel can be found without undue trial and error based on known tableting conditions for dry aluminum hydroxide gel that does not contain vanadium.
かくして、本発明によれば、下記のように含バナジウムアルミニウム化合物を有効成分とする血糖値降下、膵臓の機能強化乃至活性化、すなわち膵臓病の予防乃至治療剤が提供される。
〔1〕下記式（１）
Ｍ1-x (Ｖ)x (1)
（式中、Ｍは、乾燥水酸化アルミニウムゲル、ジヒドロキシアルミニウムアミノアセテート、水酸化アルミニウム・炭酸水素ナトリウム共沈物、合成ケイ酸アルミニウム、水酸化アルミナマグネシウム、メタケイ酸アルミン酸マグネシウム、ショ糖硫酸エステルアルミニウム塩、から選ばれた少なくとも1種のアルミニウム化合物であり、ｘの値は
0＜ｘ≦0.1である。）で表される膵臓機能強化乃至活性化剤用アルミニウム化合物粒子。
〔2〕前記〔1〕の血糖値降下剤。
〔3〕前記〔1〕の糖尿病予防乃至治療剤。
〔4〕前記〔1〕の顆粒剤。
〔5〕前記〔1〕の液剤。
〔6〕前記〔1〕の錠剤
Thus, according to the present invention, a blood glucose level lowering, pancreatic function enhancement or activation, that is, a preventive or therapeutic agent for pancreatic disease, comprising a vanadium-containing aluminum compound as an active ingredient as described below is provided.
[1] The following formula (1)
M 1-x (V) x (1)
(In the formula, M is dry aluminum hydroxide gel, dihydroxyaluminum aminoacetate, aluminum hydroxide / sodium hydrogencarbonate coprecipitate, synthetic aluminum silicate, magnesium alumina hydroxide, magnesium aluminate metasilicate, aluminum sucrose sulfate ester At least one aluminum compound selected from salts, and the value of x is
0 <x ≦ 0.1. The pancreas function strengthening thru | or activator aluminum compound particle | grains represented by this.
[2] The hypoglycemic agent according to [1].
[3] The preventive or therapeutic agent for diabetes according to [1].
[4] Granule of said [1].
[5] The liquid agent according to [1].
[6] Tablet of [1] above
実施例に基づき、本発明を詳細に説明する。
実施例において、アルミニウム化合物粒子の（a）Ｖの分析値、（ｂ）平均2次粒子径、（ｃ）BET法比表面積は以下に記載する測定法によって測定された値を意味する。
（a）Ｖの分析
原子吸光法により測定した。
（ｂ）平均2次粒子径
MICROTRAC粒度分布計SPAタイプ（LEEDS＆NORTHRUP INSTRUMENTS社製）を用いて測定決定する。
試料粉末700ｍｇを70ｍLの水に加えて、超音波（NISSEI社製、MODEL US-300,電流300μA）で3分間分散処理した後、その分散液の2-4ｍLを採って、250ｍLの脱気水を収容した上記粒度分布計の試料室に加え、分析計を作動させて8分間その懸濁液を循環した後、粒度分布を測定する。合計2回の測定を行い、それぞれの測定について得られた50％累積2次粒子径の算術平均値を算出して、試料の平均2次粒子径とする。
（ｃ）BET法比表面積
液体窒素の吸着法により測定した。
Based on the actual施例, the present invention will be described in detail.
In the examples, (a) V analysis value, (b) average secondary particle size, and (c) BET specific surface area of aluminum compound particles mean values measured by the measurement methods described below.
(A) Analytical measurement of V Measured by atomic absorption.
(B) Average secondary particle size
Measurement is determined using a MICROTRAC particle size distribution analyzer SPA type (manufactured by LEEDS & NORTHHRUP INSTRUMENTS).
Add 700 mg of the sample powder to 70 mL of water, disperse with ultrasonic waves (NISSEI, MODEL US-300, current 300 μA) for 3 minutes, take 2-4 mL of the dispersion, and then add 250 mL of deaerated water. In addition to the sample chamber of the particle size distribution meter containing the above, the analyzer is operated and the suspension is circulated for 8 minutes, and then the particle size distribution is measured. The measurement is performed twice in total, and the arithmetic average value of the 50% cumulative secondary particle diameter obtained for each measurement is calculated to obtain the average secondary particle diameter of the sample.
(C) BET method Specific surface area It was measured by the liquid nitrogen adsorption method.
［本発明の無機化合物粒子の製造（１）］
硫酸アルミニウム１．０モル／Ｌ、塩化バナジウム２×10−３モル／Ｌの水溶液、および炭酸ナトリウム０．７５モル／Ｌの水溶液をそれぞれ調製し、実容積１Ｌの連続反応槽に予め水を５００ｍＬ入れ、攪拌しながらそれぞれの流量が５．６Ｌ／分、２７．８Ｌ／分となるように定量ポンプで供給し、室温で５時間反応した。得られたスラリーをフィルターにて吸引脱水し、ケーキを形成させ１０倍量のイオン交換水で水洗した後、１．０Ｍ／Ｌ塩酸水溶液をケーキ中の固形物重量に対して１０倍量で洗浄した後、同様に１０倍量のイオン交換水で洗浄した。得られた洗浄済みケーキを固形分で２００ｇ／Ｌに再乳化し、スプレードライヤーにて乾燥した。
得られた乾燥物を分析した結果
（Ａｌ（ＯＨ）３）０．９９９（Ｖ）０．００１であった。
[Production of Inorganic Compound Particles of the Present Invention (1)]
An aqueous solution of 1.0 mol / L aluminum sulfate, an aqueous solution of 2 × 10 −3 mol / L of vanadium chloride, and an aqueous solution of 0.75 mol / L sodium carbonate were prepared, respectively, and 500 mL of water was previously added to a continuous reaction tank having an actual volume of 1 L. While being stirred, the flow rate was 5.6 L / min and 27.8 L / min, respectively, and the mixture was supplied with a metering pump and reacted at room temperature for 5 hours. The obtained slurry was sucked and dehydrated with a filter to form a cake, washed with 10 times the amount of ion-exchanged water, and then washed with 1.0 M / L hydrochloric acid aqueous solution 10 times the weight of solids in the cake. After that, it was similarly washed with 10 times the amount of ion-exchanged water. The washed cake obtained was re-emulsified to a solid content of 200 g / L and dried with a spray dryer.
As a result of analyzing the obtained dried product, it was (Al (OH) 3 ) 0.999 (V) 0.001 .
［本発明の無機化合物粒子の製造（２）］
硫酸アルミニウム０．５２４モル／Ｌ、塩化バナジウム１×10−３モル／Ｌの水溶液、およびＮａ２Ｏ ０．５６モル／Ｌ、ＳｉＯ２ １．６８モル／Ｌの３号水ガラス水溶液をそれぞれ調製し、実容積１Ｌの連続反応槽に予め水を５００ｍＬ入れ、攪拌しながらそれぞれの流量が８．８Ｌ／分、２４．６Ｌ／分となるように定量ポンプで供給し、室温で５時間反応した。得られたスラリーをフィルターにて吸引脱水し、ケーキを形成させ１０倍量のイオン交換水で水洗した。得られた洗浄済みケーキを固形分で２００ｇ／Ｌに再乳化し、スプレードライヤーにて乾燥した。
得られた乾燥物を分析した結果
（Ａｌ２Ｏ３・９ＳｉＯ２・ｎＨ２Ｏ）０．９９８（Ｖ）０．００２であった。
[Production of inorganic compound particles of the present invention (2)]
An aqueous solution of 0.524 mol / L of aluminum sulfate and 1 × 10 −3 mol / L of vanadium chloride and an aqueous solution of No. 3 water glass of 0.56 mol / L of Na 2 O and 1.68 mol / L of SiO 2 were prepared. Then, 500 mL of water was previously placed in a continuous reaction tank having an actual volume of 1 L, and were supplied with a metering pump so that the respective flow rates would be 8.8 L / min and 24.6 L / min while stirring, and reacted at room temperature for 5 hours. . The obtained slurry was suction dehydrated with a filter to form a cake, which was washed with 10 times the amount of ion-exchanged water. The washed cake obtained was re-emulsified to a solid content of 200 g / L and dried with a spray dryer.
The resulting dried product was analyzed with (Al 2 O 3 · 9SiO 2 · nH 2 O) was 0.998 (V) 0.002.
実施例1および2で得られたサンプルを用い、ラットによる耐糖能試験を行った。
（試験方法）
一晩（２０時間以上）絶食させたラット（ＳＤ系 雄 6〜7週齢、6匹/サンプル）を使用した。
グルコースを1ｇ/10ｍＬ/Ｋｇでラットに経口投与した後、直ちに試料10ｍＬ/Ｋｇを、ディスポーザブル注射筒及びラット用胃ゾンデを用いて強制的に経口投与した。グルコース、及び試料投与前、投与３０分及び６０分後に、それぞれ尾静脈より採血し、小型電極式血糖測定機器（アントセンスII, ダイキン工業(株)）を用いて血糖値を測定した。
結果を表1に示す。
Using a sample obtained by the actual Example 1 and 2 were subjected to glucose tolerance test in rats.
(Test method)
Rats (SD male 6-7 weeks old, 6 animals / sample) fasted overnight (over 20 hours) were used.
After glucose was orally administered to rats at 1 g / 10 mL / Kg, immediately, 10 mL / Kg of sample was forcibly orally administered using a disposable syringe and a rat stomach sonde. Glucose and blood were collected from the tail vein before and 30 minutes and 60 minutes after administration of the sample, respectively, and the blood glucose level was measured using a small electrode blood glucose measurement device (Antosense II, Daikin Industries, Ltd.).
The results are shown in Table 1.
《結果》
実施例１の２０時間以上絶食時のラットの血糖値は約６５mg/dLであった。投与３０分後には血糖値は投与前と較べて有意に上昇し、約１５７mg/dLにまで達した。その後、投与６０分後に徐々に血糖値は低下し約1４８mg/dLの値となった。
実施例２の２０時間以上絶食時のラットの血糖値は約７２mg/dLであった。投与３０分後には血糖値は投与前と較べて有意に上昇し、約1４７mg/dLにまで達した。その後、投与６０分後に徐々に血糖値は低下し約１４０mg/dLの値となった。
< Result >
The blood glucose level of the rat at the time of fasting for 20 hours or more in Example 1 was about 65 mg / dL. After 30 minutes from the administration, the blood glucose level significantly increased as compared to before administration, and reached about 157 mg / dL. Thereafter, 60 minutes after administration, the blood glucose level gradually decreased to a value of about 148 mg / dL.
The blood glucose level of the rat at the time of fasting for 20 hours or more in Example 2 was about 72 mg / dL. After 30 minutes from the administration, the blood glucose level significantly increased as compared to before administration, and reached about 147 mg / dL. Thereafter, 60 minutes after administration, the blood glucose level gradually decreased to about 140 mg / dL .
Claims (4)
Ｍ1-x (Ｖ)x (1)
（式中、Ｍ は、乾燥水酸化アルミニウムゲル、ジヒドロキシアルミニウムアミノアセテート、水酸化アルミニウム・炭酸水素ナトリウム共沈物、合成ケイ酸アルミニウム、水酸化アルミナマグネシウムなる群より選ばれた少なくとも1種のアルミニウム化合物であり、ｘの範囲が、０．００１＜ｘ＜０．０５、すなわち、含バナジウムアルミニウム化合物におけるバナジウムの量は、金属バナジウム換算で０．００１重量％から０．０５重量％以下の範囲である。）で表される含バナジウムアルミニウム化合物を有効成分とする血糖値降下剤。 A water-soluble vanadium salt is added to a water-soluble aluminum salt as a raw material, a mixed aqueous solution of an aluminum salt and a vanadium salt is prepared in advance, and a trace amount of vanadium ions is dissolved or coprecipitated in an aluminum compound (1) ),
M 1-x (V) x (1)
(Wherein M is at least one aluminum compound selected from the group consisting of dry aluminum hydroxide gel, dihydroxyaluminum aminoacetate, aluminum hydroxide / sodium hydrogencarbonate coprecipitate, synthetic aluminum silicate, and magnesium aluminate hydroxide ) And the range of x is 0.001 <x <0.05, that is, the amount of vanadium in the vanadium-containing aluminum compound is in the range of 0.001 wt% to 0.05 wt% or less in terms of metal vanadium. .) A hypoglycemic agent comprising a vanadium-containing aluminum compound represented by
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2009245178A JP5352416B2 (en) | 2009-10-26 | 2009-10-26 | A blood glucose level lowering agent comprising vanadium-containing aluminum compound as an active ingredient |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2009245178A JP5352416B2 (en) | 2009-10-26 | 2009-10-26 | A blood glucose level lowering agent comprising vanadium-containing aluminum compound as an active ingredient |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2011088870A JP2011088870A (en) | 2011-05-06 |
| JP2011088870A5 JP2011088870A5 (en) | 2011-08-11 |
| JP5352416B2 true JP5352416B2 (en) | 2013-11-27 |
Family
ID=44107462
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009245178A Active JP5352416B2 (en) | 2009-10-26 | 2009-10-26 | A blood glucose level lowering agent comprising vanadium-containing aluminum compound as an active ingredient |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JP5352416B2 (en) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5352411B2 (en) * | 2009-10-14 | 2013-11-27 | 協和化学工業株式会社 | Hypoglycemic agent or pancreatic function enhancing or activating agent comprising hydrotalcite compound particles as an active ingredient |
| JP5390334B2 (en) * | 2009-10-15 | 2014-01-15 | 協和化学工業株式会社 | A blood glucose level lowering agent or pancreatic function enhancing or activating agent comprising vanadium solid solution magnesium oxide compound particles as an active ingredient. |
| TW201922121A (en) * | 2017-09-29 | 2019-06-16 | 日商親廣產業股份有限公司 | Sugar consumption promoting agent |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP3942740B2 (en) * | 1998-07-31 | 2007-07-11 | 独立行政法人科学技術振興機構 | Amino acid derivatives and oxovanadium (IV) complexes |
| JP4005260B2 (en) * | 1999-03-30 | 2007-11-07 | 独立行政法人科学技術振興機構 | 2-mercapto-pyridine-N-oxide derivative / oxovanadium (IV) complex |
| JP3905255B2 (en) * | 1999-06-29 | 2007-04-18 | 独立行政法人科学技術振興機構 | Bis (halogen picolinate) oxovanadium |
| JP5352411B2 (en) * | 2009-10-14 | 2013-11-27 | 協和化学工業株式会社 | Hypoglycemic agent or pancreatic function enhancing or activating agent comprising hydrotalcite compound particles as an active ingredient |
-
2009
- 2009-10-26 JP JP2009245178A patent/JP5352416B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| JP2011088870A (en) | 2011-05-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6938425B2 (en) | Lanthanum carbonate hydroxide, lanthanum oxycarbonate and its production and usage | |
| JP6049801B2 (en) | Mixed metal compound | |
| KR101108820B1 (en) | Rare earth metal compounds, methods of making, and methods of using the same | |
| KR101552183B1 (en) | Mixed metal compounds for treatment of hyperphos phataemia | |
| CN102143742A (en) | Phosphate binding materials and their uses | |
| JP5352416B2 (en) | A blood glucose level lowering agent comprising vanadium-containing aluminum compound as an active ingredient | |
| JP2011088870A5 (en) | ||
| KR20090098940A (en) | Gastric antacid | |
| JP2006070022A (en) | Medicament or food additive containing cyclodextrin | |
| JP5352411B2 (en) | Hypoglycemic agent or pancreatic function enhancing or activating agent comprising hydrotalcite compound particles as an active ingredient | |
| JP2011084491A5 (en) | ||
| CN1688511A (en) | Rare earth metal compounds, methods of making, and methods of using the same | |
| JP5390334B2 (en) | A blood glucose level lowering agent or pancreatic function enhancing or activating agent comprising vanadium solid solution magnesium oxide compound particles as an active ingredient. | |
| EP3954391A1 (en) | Composition comprising clay mineral complex for prevention, alleviation, and treatment of inflammatory bowel disease, preparation method for composition, and method for alleviation and treatment for inflammatory bowel disease | |
| JP2011084505A5 (en) | ||
| KR101225898B1 (en) | Agent for treating ulcer | |
| US8974835B2 (en) | Gastric ulcer therapeutic agent | |
| US20230233603A1 (en) | Pharmaceutical composition containing cerium compound as active ingredient | |
| JP2010265208A (en) | Composite magnesium oxide particle for enhancing or activating pancreatic function | |
| JP2010265207A (en) | Composite hydrotalcite particle for enhancing or activating pancreatic function | |
| CN111317123A (en) | Papaya enzyme composition for improving and promoting functions of digestive absorption system, preparation method and composite nano preparation | |
| KR20210091185A (en) | Treatment methods using mixed metal compounds | |
| CA2650368A1 (en) | An agent for treating and/or preventing osteoporosis, comprising oceanic mineral components | |
| JP2009263301A (en) | Ulcer treating agent | |
| JP2009263294A (en) | Agent for supressing/treating ulcer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20110621 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20110621 |
|
| RD02 | Notification of acceptance of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7422 Effective date: 20110621 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20110622 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20130319 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20130520 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20130815 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20130826 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 5352416 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| S111 | Request for change of ownership or part of ownership |
Free format text: JAPANESE INTERMEDIATE CODE: R313111 |
|
| R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |